Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$6.07
+0.02 (+0.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $155.2M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.2B
P/E
13.5x
↓EV/EBITDA
4.3x
↓ROE
5.6%
↑Gross Margin
18.8%
↓Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.3%
FCF CAGR
-6.6%
FCF margin
4.8%
FCF / Net income
1.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.75B · net income $289.9M · FCF $418.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.75B | $8.75B | $8.47B | $8.10B | $7.50B |
| Net Income | $289.9M | $289.9M | $470.0M | $496.5M | $411.1M |
| EBITDA | $988.9M | $988.9M | $1.11B | $1.09B | $1.01B |
| EPS | 0.42 | 0.42 | 0.68 | 0.72 | 0.61 |
| Gross Margin | 18.8% | 18.8% | 24.1% | 29.5% | 27.2% |
| Operating Margin | 5.0% | 5.0% | 7.0% | 7.6% | 7.2% |
| Net Margin | 3.3% | 3.3% | 5.6% | 6.1% | 5.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 0.33 | 0.30 | 0.34 |
| Current Ratio | 1.76 | 1.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $418.1M | $418.1M | $155.2M | $-59.9M | $513.5M |
| Returns | |||||
| ROE | 5.6% | 5.6% | 9.4% | 10.9% | 10.0% |
| Valuation | |||||
| P/E | 13.49 | 13.49 | 8.81 | 7.83 | 12.69 |
| EV/EBITDA | 4.32 | 4.32 | 4.09 | 3.97 | 5.38 |
| P/B | 0.80 | 0.80 | 0.83 | 0.85 | 1.26 |
| Growth & Yield | |||||
| Revenue Growth | 3.4% | 3.4% | 4.5% | 8.0% | — |
| EPS Growth | -38.2% | -38.2% | -5.6% | 18.0% | — |
| Dividend Yield | 9.5% | 9.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
8.6%
EPS terminal req.
$0.54
Spread vs growth
-46.9%
5Y implied EPS CAGR
9.2%
EPS terminal req.
$0.65
Spread vs growth
-47.4%
10Y implied EPS CAGR
9.6%
EPS terminal req.
$1.05
Spread vs growth
-47.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.2%
Start / end P/E
8.7x → 14.5x
EPS bridge
0.68 → 0.42
Residual
-25.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.